Chronic Obstructive Pulmonary Disease Clinical Trial
Official title:
Methodological Validation of an Intermittent Shuttle Walking Protocol in the Context of Pulmonary Rehabilitation in Patients With Advanced COPD
In the UK, field-based walking is prescribed in the pulmonary rehabilitation (PR) setting as
a convenient, less resource-intensive, and highly responsive exercise modality in COPD
patients. However, endurance time during the implementation of field-based walking protocols,
such as the endurance shuttle walking (ESW) protocol, is limited to only a few minutes
secondary to intense exertional symptoms. It therefore seems sensible to develop an
intermittent field-based walking protocol that would prolong endurance time and walking
distance compared to the commonly implemented in the PR setting continuous ESW protocol. The
aim of this study is three-fold: 1) to identify whether an intermittent shuttle walking
protocol significantly prolongs walking distance compared to the widely implemented
continuous ESW protocol in the PR setting in patients with advanced COPD; 2) to investigate
the test re-test reliability of the distance walked during the intermittent shuttle walking
protocol; and 3) to explore patients' and health care professionals' experiences of
implementing the intermittent walking protocol and the perceived factors affecting the
implementation of these protocols in the PR setting.
The study hypothesis is that the intermittent shuttle walking protocol would be associated
with lower dynamic hyperinflation and breathlessness, thereby facilitating an increase in
walking distance compared to the continuous ESW protocol.
The same group of patients with advanced COPD will initially perform an incremental shuttle
walk test (ISWT) (visit 1) to establish peak walking speed and subsequently patients will
perform the continuous ESW protocol (visit 2) at a walking speed corresponding to 85% of peak
walking speed to the limit of tolerance. On two additional visits (visits 3 and 4) patients
will perform two intermittent shuttle walking protocols to the limit of tolerance by
alternating 1-min walking bouts at a walking speed corresponding to 85% peak walking speed
(equivalent to the ESW protocol) with 1-min rest periods in between walking bouts to
establish the reproducibility of this protocol. Focus group interviews with patients and
healthcare professionals will be conducted to explore perceptions of undertaking and
implementing, respectively the intermittent walking protocol.
Although previous research in the area of pulmonary rehabilitation in COPD has documented
that high intensity exercise induces greater benefits than moderate intensity exercise,
patients with advanced COPD patients cannot sustain sufficiently high intensities for long
periods of time due to exertional breathlessness. While patients are limited by
breathlessness during continuous modes of exercise, intermittent exercise is considered to be
a good alternative strategy for patients with advanced COPD as it is associated with reduced
exertional symptoms. Intermittent exercise consists of repeated brief bouts of physical
activity at a high intensity alternated with short periods of recovery. The rationale for the
implementation of intermittent exercise in healthy people and athletes has been the capacity
to impose high loads to peripheral muscles without overloading the cardiorespiratory system.
Working at high intensities with limited exertional symptoms enables severe COPD patients to
achieve greater exercise volumes and in extend greater peripheral muscle adaptations, thereby
improving exercise tolerance. International (ATS/ERS) and national (BTS) position statements
for pulmonary rehabilitation recommend intermittent exercise for patients with advanced COPD.
Despite the well-documented benefits of intermittent exercise, very few pulmonary
rehabilitation centres in the UK employ this modality. The reason is that most of the
community-based pulmonary rehabilitation programmes lack of infrastructure (stationary cycle
ergometers, treadmills, rowing machines, etc.) and healthcare professionals to implement
interval exercise. Hence, it is necessary to develop alternative, easily implemented and
affordable, in terms of symptoms, exercise particularly for patients with advanced COPD
across the community- and hospital- based pulmonary rehabilitation setting in the UK.
In the UK, field-based walking training is prescribed in the PR setting as a convenient, less
resource-intensive, and highly responsive exercise modality in patients with COPD. However,
in 2018, the National COPD Audit Report, reported that only 62% of enrolled patients
completed a PR programme, highlighting significant drop-out rates (38%) between initial
assessment and programme completion. Intense exertional symptoms during the prescribed
exercise regimes was the main identified factor responsible for non-completion rates. In
1999, Revill et al, introduced a standardized, externally-paced (continuous) endurance
shuttle walk (ESW) protocol as a highly responsive and repeatable assessment tool to measure
endurance capacity. The ESW protocol sustained at a relatively high intensity (85% peak
walking speed derived by the Incremental Shuttle Walk Test - ISWT) is commonly employed today
as a walking training modality in the PR setting across the UK. However, endurance time
during implementation of ESW protocol is limited to only a few minutes (5-8 minutes)
secondary to intense exertional symptoms. In particular, both breathlessness and leg
discomfort are considered to limit endurance time during the ESW protocol, thus suggesting
that it is a highly physically demanding task for advanced COPD patients.
It therefore seems sensible to develop an intermittent shuttle walking protocol imposing
sufficiently intense loads to the cardiorespiratory system and the locomotor muscles without
inducing intense exertional symptoms. In turn, this would prolong endurance time and walking
distance compared to the commonly implemented continuous ESW protocol. It is envisaged that
an intermittent walking protocol for patients with advanced COPD will facilitate
participation and successful completion of a PR programme.
Research Aims
1. To identify whether an intermittent shuttle walking protocol is associated with
tolerable exertional symptoms, thereby prolonging walking distance compared to the
widely implemented continuous ESW protocol in the PR settings for patients with advanced
COPD.
2. To investigate the reproducibility of the distance walked during the intermittent
shuttle walking protocol.
3. To explore both patients' and health care professionals' experiences of undertaking and
implementing, respectively the intermittent shuttle walking and the perceived factors
affecting the implementation of this protocol in the PR setting.
Research Objectives
1. To compare walking distance, cardiorespiratory and symptom responses (breathlessness and
leg discomfort) of an intermittent shuttle walking protocol (sustained at 85% of peak
walking speed) to the commonly applied continuous ESW protocol (also sustained at 85% of
peak walking speed) in the PR setting.
2. To evaluate the test-retest reliability of distance walked, cardiorespiratory and
symptom responses during the intermittent shuttle walking protocols.
3. To explore patients' preferences of undertaking an intermittent shuttle walking
protocol, and the health care professionals' perceived barriers and facilitators
affecting the implementation of this protocol in the pulmonary rehabilitation setting.
Study Design
1. A cross sectional observational study to compare distance walked, cardiorespiratory
responses and symptoms of patients undertaking two shuttle walking protocols, namely the
continuous endurance shuttle walking (ESW) and the intermittent shuttle walking
protocol.
2. A test-retest reliability study to evaluate the validity of the intermittent shuttle
walking protocol in terms of walking distance, cardiorespiratory responses and symptoms.
3. A qualitative focus group study to explore patients' preferences of undertaking the
intermittent or continuous ESW protocols and healthcare professionals' perceived factors
affecting the implementation of these protocols in the PR setting.
Study population
COPD patients will be recruited from those referred to the Pulmonary Rehabilitation programme
at RVI Hospital in Newcastle upon Tyne. Potentially eligible patients will be identified by
the physiotherapy team within the Trust, who will provide initial information about the
study. Delegated investigators will confirm eligibility and discuss full details of the
trial. Patients will be given time to consider participation in the trial before written
informed consent is obtained.
Planned Interventions
Following confirmation of eligibility, informed consent and baseline lung assessment, all
patients will be asked initially during the first visit to perform an incremental shuttle
walk test (ISWT) to the limit of tolerance to establish peak walking speed without prior
practice. The test will be developed in a 10-m course corridor, and it will be
externally-paced via a recorded metronome that gives a signal for each stride. The walking
pace will be increased every minute and the test will be terminated when the individual is no
longer able to keep up the pace or stops due to intolerable exertional symptoms.
Subsequently, during the second visit all patients will perform the continuous endurance
shuttle walk protocol (ESW) to the limit of tolerance at 85% peak walking speed derived by
the ISWT (visit 1). During the ESW protocol patients will receive standardized instructions
to walk for as long as possible. No further encouragement will be provided during the
exercise performance. The test will be terminated when the individual is no longer able to
keep up the pace or stops due to intolerable exertional symptoms.
Following completion of the ESW protocol, patients will perform on two different days two
intermittent shuttle walking protocols to the limit of tolerance (visits 3 & 4) by
alternating 1-min walking bouts sustained at a walking speed equivalent to 85% peak
(equivalent to the continuous ESW protocol) with 1-min rest periods. To obtain test re-test
reliability in terms of distance walked, of cardiorespiratory and symptoms responses this
intermittent shuttle walking protocol will be repeated in visit 4 (Diagram 4). The test will
be terminated when the individual is no longer able to keep up the pace or stops due to
intolerable exertional symptoms.
Throughout the ISWT, the ESW and the two intermittent protocols, pulmonary gas exchange and
ventilatory variables will be recorded breath-by-breath (K4b2, Cosmed,). Cardiac output,
stroke volume and heart rate will be assessed by a portable cardio-impedance cardiography
system (Physio flow, Manatec). Percentage arterial oxygen saturation (SpO2) will be measured
by a pulse oximeter. Throughout testing, changes in operational lung volumes will be
dynamically evaluated by performing inspiratory capacity (IC) manoeuvres. Patients will score
the intensity of their breathlessness and leg discomfort using the 1-10 Borg's scale every
minute during the ESW and the intermittent walking protocols.
3. Qualitative focus group study (semi-structured interviews)
Study Outcomes:
The primary outcome is the distance walked (in meters) during the intermittent shuttle
walking protocol compared to the widely implemented continuous ESW protocol in the PR setting
for patients with advanced COPD.
Secondary Outcomes:
- Cardiorespiratory responses (ventilatory and circulatory responses)
- Exertional Symptoms (breathlessness and leg discomfort)
- Acceptability and feasibility (assessed by semi-structured interviews)
Sample Size Calculation
The calculation is based on the minimal important difference estimates (MID) of 82 (m) of the
ESW protocol and the standard deviation (SD) of 113 (m) between the different performances of
ESW walked distance improvement from the same study. Using an alpha significance level of
0.05 (2-sided) and 80% power, a minimum sample size of 17 was calculated to be sufficient. To
compensate for possible drop-outs (i.e. 20%) across the different assessment points over a
period of 12 months, 20 patients will be recruited to allow the allocation of the different
protocols with ordered sequence across the group of COPD patients.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05102305 -
A Multi-center,Prospective, OS to Evaluate the Effectiveness of 'NAC' Nebulizer Therapy in COPD (NEWEST)
|
||
Completed |
NCT01867762 -
An Effectiveness and Safety Study of Inhaled JNJ 49095397 (RV568) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
|
Phase 2 | |
Recruiting |
NCT05562037 -
Stepped Care vs Center-based Cardiopulmonary Rehabilitation for Older Frail Adults Living in Rural MA
|
N/A | |
Terminated |
NCT04921332 -
Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD
|
N/A | |
Completed |
NCT03089515 -
Small Airway Chronic Obstructive Disease Syndrome Following Exposure to WTC Dust
|
N/A | |
Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
Recruiting |
NCT05552833 -
Pulmonary Adaptive Responses to HIIT in COPD
|
N/A | |
Recruiting |
NCT05835492 -
A Pragmatic Real-world Multicentre Observational Research Study to Explore the Clinical and Health Economic Impact of myCOPD
|
||
Recruiting |
NCT05631132 -
May Noninvasive Mechanical Ventilation (NIV) and/or Continuous Positive Airway Pressure (CPAP) Increase the Bronchoalveolar Lavage (BAL) Salvage in Patients With Pulmonary Diseases?
|
N/A | |
Completed |
NCT03244137 -
Effects of Pulmonary Rehabilitation on Cognitive Function in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease
|
||
Not yet recruiting |
NCT03282526 -
Volume Parameters vs Flow Parameters in Assessment of Reversibility in Chronic Obstructive Pulmonary Disease
|
N/A | |
Completed |
NCT02546700 -
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 2 | |
Withdrawn |
NCT04446637 -
Acute Bronchodilator Effects of Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination vs Salbutamol 100 mcg Inhaler Plus Ipratropium 20 mcg Inhalation Aerosol Free Combination in Patients With Stable COPD
|
Phase 3 | |
Completed |
NCT04535986 -
A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD
|
Phase 3 | |
Recruiting |
NCT05865184 -
Evaluation of Home-based Sensor System to Detect Health Decompensation in Elderly Patients With History of CHF or COPD
|
||
Completed |
NCT03256695 -
Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Completed |
NCT03295474 -
Telemonitoring in Pulmonary Rehabilitation: Feasibility and Acceptability of a Remote Pulse Oxymetry System.
|
||
Withdrawn |
NCT04042168 -
Implications of Appropriate Use of Inhalers in Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 4 | |
Completed |
NCT03414541 -
Safety And Efficacy Study Of Orally Administered DS102 In Patients With Chronic Obstructive Pulmonary Disease
|
Phase 2 | |
Completed |
NCT02552160 -
DETECT-Register DocumEnTation and Evaluation of a COPD Combination Therapy
|